SBIO ALPS Medical Breakthroughs ETF
Issuer
ALPS Funds
Inception
Dec 30, 2014
AUM
$187.1M
Expense ratio
0.50%
Yield
—
Asset class
Equity
Holdings
103
Last price
$55.04
The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
+21.3%
2025-11-13low 45.27 · high 70.792026-11-13
Performance
| 1M | 3M | YTD | 1Y | 3Y ann. | 5Y ann. | |
|---|---|---|---|---|---|---|
| SBIO | +6.6% | -17.8% | +7.5% | +21.6% | +32.0% | +4.0% |
| Equity average (4625 funds) | -2.1% | +2.7% | +87.6% | +61193.5% | +13.9% | +2.3% |
Insider activity in the holdings
Open-market insider buying across this fund’s holdings over 90 days, weighted by holding weight: +$163K net.
| Holding | Weight | Insiders bought | Insiders sold |
|---|---|---|---|
| RAPP Rapport Therapeutics Inc. | 0.81% | $22.0M | $4.5M |
| IMTX Immatics NV | 0.64% | $7.5M | $0 |
| TENX Tenax Therapeutics Inc. | 0.04% | $6.4M | $0 |
| KURA Kura Oncology Inc. | 0.43% | $2.4M | $1.7M |
| XENE Xenon Pharmaceuticals Inc. | 2.60% | $1.7M | $426K |
| RLMD Relmada Therapeutics Inc. | 0.29% | $1.7M | $0 |
| EIKN Eikon Therapeutics Inc. | 0.21% | $1.0M | $0 |
| AGMB AgomAb Therapeutics NV | 0.20% | $503K | $0 |
| NAMS Newamsterdam Pharma Co. NV | 1.56% | $227K | $4.7M |
| SPTX Seaport Therapeutics Inc. | 0.71% | $99K | $0 |
| DYN Dyne Therapeutics Inc. | 2.08% | $40K | $248K |
| CMPX Compass Therapeutics Inc. | 0.10% | $21K | $0 |
| TYRA Tyra Biosciences Inc. | 0.77% | $20K | $0 |
| XFOR X4 Pharmaceuticals Inc. | 0.20% | $12K | $34K |
Holdings · as of Nov 13, 2026
| # | Holding | Weight |
|---|---|---|
| 1 | ORKA Oruka Therapeutics Inc. | 4.54% |
| 2 | CGON CG oncology Inc. | 4.06% |
| 3 | MANE VeraDermics Inc. | 3.70% |
| 4 | DNTH Dianthus Therapeutics Inc. | 3.38% |
| 5 | EWTX Edgewise Therapeutics Inc. | 3.25% |
| 6 | TVTX Travere Therapeutics Inc. | 3.17% |
| 7 | DFTX Definium Therapeutics Inc. | 2.90% |
| 8 | XENE Xenon Pharmaceuticals Inc. | 2.60% |
| 9 | RLAY Relay Therapeutics Inc. | 2.59% |
| 10 | AMLX Amylyx Pharmaceuticals Inc. | 2.45% |
| 11 | VRDN Viridian Therapeutics Inc. | 2.26% |
| 12 | TARS Tarsus Pharmaceuticals Inc. | 2.21% |
| 13 | IRON Disc Medicine Inc. | 2.09% |
| 14 | DYN Dyne Therapeutics Inc. | 2.08% |
| 15 | ACAD ACADIA Pharmaceuticals Inc. | 2.04% |
| 16 | IDYA Ideaya Biosciences Inc. | 1.99% |
| 17 | DNLI Denali Therapeutics Inc. | 1.98% |
| 18 | VCEL Vericel Corp. | 1.92% |
| 19 | ZLAB Zai Lab Ltd. | 1.92% |
| 20 | XNCR Xencor Inc. | 1.86% |
| 21 | MBX MBX Biosciences Inc. | 1.72% |
| 22 | NAMS Newamsterdam Pharma Co. NV | 1.56% |
| 23 | LKFT Lakefront Biotherapeutics NV | 1.48% |
| 24 | CLDX Celldex Therapeutics Inc. | 1.47% |
| 25 | PVLA Palvella Therapeutics Inc. | 1.44% |
| 26 | IMNM Immunome Inc. | 1.39% |
| 27 | VERA Vera Therapeutics Inc. | 1.37% |
| 28 | MAZE Maze Therapeutics Inc. | 1.31% |
| 29 | BCRX BioCryst Pharmaceuticals Inc. | 1.28% |
| 30 | AGIO Agios Pharmaceuticals Inc. | 1.24% |
| 31 | ZBIO Zenas Biopharma Inc. | 1.18% |
| 32 | KLRA Kailera Therapeutics Inc. | 1.12% |
| 33 | SRPT Sarepta Therapeutics Inc. | 1.11% |
| 34 | STOK Stoke Therapeutics Inc. | 1.11% |
| 35 | SLS SELLAS Life Sciences Group Inc. | 1.06% |
| 36 | GENB Generate Biomedicines Inc. | 1.06% |
| 37 | IMCR Immunocore Holdings PLC | 1.03% |
| 38 | NUVB Nuvation Bio Inc. | 0.93% |
| 39 | GPCR Structure Therapeutics Inc. | 0.93% |
| 40 | TSHA Taysha Gene Therapies Inc. | 0.90% |
| 41 | MLYS Mineralys Therapeutics Inc. | 0.90% |
| 42 | LBRX LB Pharmaceuticals Inc. | 0.90% |
| 43 | MNKD MannKind Corp. | 0.88% |
| 44 | NKTR Nektar Therapeutics | 0.83% |
| 45 | CMPS Compass Pathways PLC | 0.83% |
| 46 | RAPP Rapport Therapeutics Inc. | 0.81% |
| 47 | ANRO Alto Neuroscience Inc. | 0.79% |
| 48 | TYRA Tyra Biosciences Inc. | 0.77% |
| 49 | VOR Vor BioPharma Inc. | 0.75% |
| 50 | SGP SpyGlass Pharma Inc. | 0.73% |
| 51 | SPTX Seaport Therapeutics Inc. | 0.71% |
| 52 | IMTX Immatics NV | 0.64% |
| 53 | CRVS Corvus Pharmaceuticals Inc. | 0.58% |
| 54 | RIGL Rigel Pharmaceuticals Inc. | 0.56% |
| 55 | MGTX MeiraGTx Holdings PLC | 0.55% |
| 56 | SLDB Solid Biosciences Inc. | 0.49% |
| 57 | DCTH Delcath Systems Inc. | 0.48% |
| 58 | FLGT Fulgent Genetics Inc. | 0.44% |
| 59 | BCAX Bicara Therapeutics Inc. | 0.44% |
| 60 | FDMT 4D Molecular Therapeutics Inc. | 0.44% |
| 61 | DSGN Design Therapeutics Inc. | 0.43% |
| 62 | KURA Kura Oncology Inc. | 0.43% |
| 63 | OLMA Olema Pharmaceuticals Inc. | 0.43% |
| 64 | AVBP ArriVent Biopharma Inc. | 0.42% |
| 65 | CADL Candel Therapeutics Inc. | 0.42% |
| 66 | GERN Geron Corp. | 0.42% |
| 67 | CLYM Climb Bio Inc. | 0.41% |
| 68 | WVE Wave Life Sciences Inc. | 0.41% |
| 69 | ACRS Aclaris Therapeutics Inc. | 0.39% |
| 70 | NGNE Neurogene Inc. | 0.31% |
| 71 | OCS Oculis Holding AG | 0.30% |
| 72 | RLMD Relmada Therapeutics Inc. | 0.29% |
| 73 | TECX Tectonic Therapeutic Inc. | 0.27% |
| 74 | RZLT Rezolute Inc. | 0.24% |
| 75 | CCCC C4 Therapeutics Inc. | 0.22% |
| 76 | EIKN Eikon Therapeutics Inc. | 0.21% |
| 77 | ENTA Enanta Pharmaceuticals Inc. | 0.21% |
| 78 | CTNM Contineum Therapeutics Inc. | 0.21% |
| 79 | XFOR X4 Pharmaceuticals Inc. | 0.20% |
| 80 | AGMB AgomAb Therapeutics NV | 0.20% |
| 81 | ALT Altimmune Inc. | 0.20% |
| 82 | EVMN Evommune Inc. | 0.19% |
| 83 | ALLO Allogene Therapeutics Inc. | 0.19% |
| 84 | FULC Fulcrum Therapeutics Inc. | 0.18% |
| 85 | SABS SAB Biotherapeutics Inc. | 0.18% |
| 86 | ARCT Arcturus Therapeutics Holdings Inc. | 0.16% |
| 87 | IMRX Immuneering Corp. | 0.15% |
| 88 | IKT Inhibikase Therapeutics Inc. | 0.14% |
| 89 | BCYC Bicycle Therapeutics PLC | 0.11% |
| 90 | UPB Upstream Bio Inc. | 0.10% |
| 91 | SION Sionna Therapeutics Inc. | 0.10% |
| 92 | CMPX Compass Therapeutics Inc. | 0.10% |
| 93 | MGNX MacroGenics Inc. | 0.09% |
| 94 | TARA Protara Therapeutics Inc. | 0.09% |
| 95 | AKBA Akebia Therapeutics Inc. | 0.09% |
| 96 | ZURA Zura Bio Ltd. | 0.08% |
| 97 | IMUX Immunic Inc. | 0.07% |
| 98 | NBP NovaBridge Biosciences | 0.06% |
| 99 | AVXL Anavex Life Sciences Corp. | 0.06% |
| 100 | TENX Tenax Therapeutics Inc. | 0.04% |
| 101 | SBIO Cash Equivalent | 0.00% |
Sector breakdown
Healthcare100.0%
Country breakdown
United States92.1%
Canada2.5%
China1.9%
Netherlands1.5%
United Kingdom1.5%
Switzerland0.3%
Belgium0.2%
Distributions
| Date | Per unit |
|---|---|
| Dec 19, 2024 | $1.1735 |
| Dec 21, 2023 | $0.0711 |
| Dec 19, 2019 | $0.0158 |
| Dec 20, 2018 | $0.7841 |
| Dec 21, 2017 | $0.5795 |
Members of Congress who disclosed this ETF
| Member | Action | Amount band | Date |
|---|---|---|---|
| Thomas Richard Carper · Senate | Sell | $1K–$15K | Apr 17, 2023 |
| Thomas Richard Carper · Senate | Sell | $1K–$15K | Feb 15, 2023 |
| Thomas Richard Carper · Senate | Sell | $1K–$15K | Oct 4, 2022 |
| Thomas Richard Carper · Senate | Sell | $1K–$15K | Mar 7, 2022 |
| Thomas Richard Carper · Senate | Sell | $1K–$15K | Dec 31, 2021 |
| Thomas Richard Carper · Senate | Buy | $1K–$15K | Nov 29, 2021 |
| Thomas Richard Carper · Senate | Buy | $1K–$15K | Dec 30, 2020 |
| Thomas Richard Carper · Senate | Buy | $1K–$15K | Nov 20, 2020 |
| Thomas Richard Carper · Senate | Sell | $1K–$15K | Apr 2, 2020 |
Fund facts, prices, performance and distributions: our market-data vendor. Holdings: the vendor and SEC Form N-PORT. Insider and Congress data: InsiderBuying. Last updated Nov 13, 2026. This is historical data, not investment advice. Report a data error